Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

C03DA01 SPIRONOLACTONUM CAPS. 100 mg

VEROSPIRON 100 mg GEDEON RICHTER LTD.
C03DA01 SPIRONOLACTONUM COMPR. 25 mg

SPIRONOLACTONA 25 mg 25 mg BIO EEL SRL

C03DA01 SPIRONOLACTONUM COMPR. FILM. 25 mg

ALSPIRON 25 mg 25 mg AC HELCOR PHARMA SRL

SPIRONOLACTONA 25 mg 25 mg TERAPIA SA
C03DA01 SPIRONOLACTONUM CAPS. 50 mg

VEROSPIRON 50 mg GEDEON RICHTER LTD.

C03DA01 SPIRONOLACTONUM COMPR. FILM. 50 mg

ALSPIRON 50 mg 50 mg AC HELCOR PHARMA SRL

________________________________________________________________________________
______________________________________________________________________________

| 412 |H02AB06| PREDNISOLONUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 250 mg

INJ.

SOLU - DECORTIN H 250 250 mg MERCK KGAA

H02AB06 PREDNISOLONUM LIOF. + SOLV. PT. SOL. 50 mg

INJ.

SOLU - DECORTIN H 50 50 mg MERCK KGAA

________________________________________________________________________________

______________________________________________________________________________

| 413 |J05AB04| RIBAVIRINUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB04 RIBAVIRINUM CAPS. 200 mg

REBETOL 200 mg 200 mg SP EUROPE
J05AB04 RIBAVIRINUM COMPR. FILM. 200 mg

COPEGUS(R) 200 mg ROCHE ROMANIA SRL

________________________________________________________________________________
______________________________________________________________________________

| 414 |J05AF05| LAMIVUDINUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AF05 LAMIVUDINUM COMPR. FILM. 100 mg

ZEFFIX 100 mg 100 mg GLAXO GROUP LTD.
J05AF05 LAMIVUDINUM SOL. ORALĂ 10 mg/ml

EPIVIR 10 mg/ml 10 mg/ml GLAXO GROUP LTD.

J05AF05 LAMIVUDINUM COMPR. FILM. 150 mg

EPIVIR 150 mg 150 mg GLAXO GROUP LTD.

J05AF05 LAMIVUDINUM SOL. ORALĂ 5 mg/ml

ZEFFIX 5 mg/ml 5 mg/ml GLAXO GROUP LTD.

________________________________________________________________________________
______________________________________________________________________________

| 416 |J05AF10| ENTECAVIRUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AF10 ENTECAVIRUM COMPR. FILM. 0,5 mg

BARACLUDE 0,5 mg 0,5 mg BRISTOL-MYERS SQUIBB

PHARMA EEIG

J05AF10 ENTECAVIRUM COMPR. FILM. 1 mg

BARACLUDE 1 mg 1 mg BRISTOL-MYERS SQUIBB

PHARMA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 417 |L03AA02| FILGRASTIMUM (G-CSF)** | Protocol: B013K |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml

NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 48 MU/0.5 ml

NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V.

________________________________________________________________________________
______________________________________________________________________________

| 418 |L03AB04| INTERFERONUM ALFA 2a**** | |

|_______|_______|____________________________________________|_________________|
Tratamentul cu interferon alfa a fost asociat cu depresie şi suicid la unii pacienţi. Pacienţii cu istoric de ideaţie suicidară sau boală depresivă trebuie avertizaţi de riscuri. Trebuie monitorizat statusul psihiatric în timpul tratamentului.